watching biotechs, gold & silver
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Cantor was part of the huge secondary..."
True enough- but they're not afraid to reverse their views; ie., look at OMER, which you've expressed a positive view of in the past.
Re your "fearing the 4's...", why don't you see it as an opportunity?
Interesting tweet from AF 30 minutes ago- tangentially AUPH related:
@adamfeuerstein
29m29 minutes ago
"Elemer Piros, the Cantor Fitz sell-side analyst, dropped coverage of $OMER last night. Let that sink in. Sage Kelly’s bank, which raised $70M for $OMER last August, said no más."
BTW, he likes AUPH- from last October he said:
"Cantor analyst Elemer Piros is out with an enthusiastic take on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) on the heels of the drug maker’s R&D day that has laid forth a meaningful pathway for the next two years.
In reaction, the analyst continues to see immense value in this biotech player, reiterating an Overweight rating on AUPH stock with a $14 price target, which represents a close to 131% increase from where the stock is currently trading."
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018
Conference Call and webcast to follow
https://www.businesswire.com/news/home/20180228006340/en/Aurinia-Pharmaceuticals-Release-Fourth-Quarter-Full-Year
Definitely a heavy hitter. Here's his bio from Crunchbase:
"Michael Hayden
President of Global R&D and Chief Scientific Officer
Teva Pharmaceutical Industries
Gender
Male
Dr. Hayden has international standing as a research scientist and clinician. He has an outstanding record of leadership, innovation, and is a clinician-scientist who has spent his entire working life in research that has led directly to medicines which have made a substantial difference to patients around the world. His work in genetics and personalized medicine is internationally renowned, and he is one of the world’s leading experts on Huntington’s disease.
Dr. Hayden also has extensive experience in all stages of medicine development – from target identification, through the complete cycle of clinical development, to submission and approval processes with regulators around the world.
Currently, he is Killam Professor of Medical Genetics at the University of British Columbia, and Canada Research Chair in Human Genetics and Molecular Medicine. He is also the founder and Director/Senior Scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia.
Dr. Hayden has founded three biotechnology companies: NeuroVir; Aspreva Pharmaceuticals; and Xenon Pharmaceuticals Inc. In 2011, he was awarded the Canada Gairdner Wightman award, recognizing him as a physician-scientist who has demonstrated outstanding leadership in medicine and medical science. In 2010, he was awarded the Order of Canada, which is the highest honour that Canada can give its citizens for exceptional achievement, merit or service."
Dr. Glickman is clearly putting together a world class organization.
Thanks Vid!
Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors
Very impressive!
https://ir.auriniapharma.com/press-releases/detail/109
"Could Aurinia Pharmaceuticals Be a Millionaire-Maker Stock?
This small-cap biotech could be on the edge of something big."
https://www.fool.com/investing/2018/02/22/could-aurinia-pharmaceuticals-be-a-millionaire-mak.aspx
BC LifeSciences Company of the Year - Aurinia Pharmaceutical Inc.
Nice local honor
https://www.businesswire.com/news/home/20180219005610/en/2018-LifeSciences-BC-Annual-Award-Winners-Announced
Luna, Hotrod, Jess: Thanks for your comments.
I'm reminding myself that patience is something that I need more of.
I wonder at the bold nerve possessed by the holders of the roughly 9M shares short- what are they thinking? Obviously not about a preemptive BO.
I think they are on far more dangerous ground than the longs since they could be severely burned well before the end of P3.
Since there are now 200 sites up I think the 320 pt mark will be filled soon, and maybe well ahead of schedule. That event could give this a pop.
"Time to load up again."
To quote Marisa Tomei from "My Cousin Vinny", I think your statement is "dead-on balls accurate."
The current price makes no sense to me- I ask myself why aren't we at least $10 now?
Probably everyone would agree biotechs need not only great science, but also great management to succeed. We clearly have both here. Dr. Glickman at the helm not only knows how to execute- he gets it done.
To use a football analogy, he doesn't move the ball east and west, he moves it south to north to the goal line.
It's remarkable what he's accomplished in the last 12 months at Aurinia:
Aurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial
JAN 27, 2017
Aurinia Announces Appointment of Company Founder, Dr. Richard M. Glickman, as its New Chief Executive Officer
FEB 6, 2017
Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study
MAR 1, 2017
Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
MAR 20, 2017
Aurinia Announces Development Plans for Voclosporin in Europe and Japan
APR 6, 2017
Aurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome
APR 17, 2017
Pharma Industry Veteran Dr. George Milne Joins Aurinia’s Board of Directors
MAY 9, 2017
Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights
MAY 15, 2017
Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis
MAY 17, 2017
Aurinia Presents Additional Data from Phase Iib Aura-Lv Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks
JUN 5, 2017
Aurinia Receives National Corporate Visionary Award from the Lupus Foundation of America
OCT 12, 2017
Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome
OCT 20, 2017
Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index
DEC 11, 2017
Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors
FEB 8, 2018
Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program
FEB 14, 2018
Somebody please enlighten me re what I'm missing here- the current price seems insane to me.
GLTA
Aurinia Pharmaceuticals: Will AURORA Light The Way To Voclosporin's Approval?
https://seekingalpha.com/article/4147601-aurinia-pharmaceuticals-will-aurora-light-way-voclosporins-approval?page=2
It's definitely looking very positive, but I wouldn't be surprised if they choose to take the money at some point and leave the business development to an acquirer.
I got the impression that while Aurinia is making all the right moves in laying the groundwork for future commercialization, Dr. Glickman is very open to selling if he were offered the right price.
Time will tell. Hard not to feel good about this special situation.
Nice 24 minute presentation- Dr. Glickman sounds very confident.
Re P3: DSMB has met re safety. RG said, "Things appear to be going very well and I would be aware if things were not going well."
Enrollment on track: 200 sites with a fair number of patients in the study. A lot more sites in US, also more sites in Europe with a very high odds ratio there- "European patients do very very well in this program".
VOS program in dry eye for restasis: The market is expanding and the forecast shows it growing to be $2B market this year. 70% are not refilling prescriptions primarily due to tolerability issues, so an opportunity exists for a drug that works quicker and better.
Re commercialization mindset: RG is focused on the question of how to create the greatest value for shareholders.
Well worth a listen (and re-listen).
http://wsw.com/webcast/leerink30/auph/index.aspx
You're referring to old BR or ???
Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program
https://www.businesswire.com/news/home/20180214005223/en/Aurinia-Pharmaceuticals-Launches-New-Lupus-Nephritis-Disease
https://www.allinforlupusnephritis.com
"Aurinia Pharmaceuticals Inc (AUPH) Is an Attractive Opportunity with 75% Upside"
https://www.smarteranalyst.com/2018/02/08/aurinia-pharmaceuticals-inc-auph-attractive-opportunity-75-upside/
OK, since you said the magic word- Peter Venkman
who are you and what have you done with BR?
JOSEPH “JAY” HAGAN President and Chief Executive Officer
http://regulusrx.com/joseph-jay-hagan/
FYI, it's "you're" (you are) and not "your"
"Investors pulled $1.2 billion out of health care and biotech funds last week — the largest weekly outflow of money from the sector since February 2016, according to a new analysis.
The acceleration of investor money leaving biotech funds is reflected in plunging stock prices. The Nasdaq Biotech Index fell 4 percent in the five trading days ended on Feb. 7, the time period matching the $1.2 billion outflow."
https://www.statnews.com/2018/02/09/biotech-fund-flows/
http://regulusrx.com/joseph-jay-hagan/
Wonder if he can turn around Regulus- from $20 in 2014 to $1+ today?
Does anyone have any knowledge or a view re their prospects?
TIA for any input
Researchers Identify Potential New Target for Treating Lupus Nephritis
https://lupusnewstoday.com/2018/02/05/researchers-identified-potential-new-target-treating-lupus-nephritis/
Aurinia to Present at Leerink Partners 7th Annual Global Healthcare Conference
https://ir.auriniapharma.com/press-releases/detail/105
Not sure which is greater- the comedy or the tragedy of it
Market 101- more sellers than buyers
Could the market for Voclosporin be bigger than we think?
This survey finding by GlaxoSmithKline (manufacturer of belimumab [Benlysta]) seems to reveal a high level of ignorance re LN among medical professionals: "Fewer than 40% of rheumatologists surveyed were aware that SLE leads to organ damage in 30% to 50% of patients within five years of diagnosis. In addition, most healthcare providers accepted corticosteroid doses far exceeding the recommended clinical threshold, according to the survey."
http://formularyjournal.modernmedicine.com/formulary-journal/news/survey-uncovers-lupus-corticosteroid-treatment-issues
"Aurinia Pharmaceuticals: Potential Rewards Far Outweigh The Risks"
https://seekingalpha.com/article/4140619-aurinia-pharmaceuticals-potential-rewards-far-outweigh-risks
Nice! I'm just north of you at the moment.
Haven't yet seen Irma damage there firsthand- how is the recovery going down there?
Mallory Square, Duval St., Sunset Pier with the Tarpon rolling over- Great stuff!
Have one (or three) for me.
Yup- massive collapse. You're fortunate to have gotten out at $4.50.
Jess- thanks for the color/backstory re ARIA history of intrigue.
Much appreciated.
Onward and upward.
It would be nice to see the Baker Bros. or similar take a sizable position.
Good luck to the patient longs.
Ariadnes? I missed all that fun, but I'm guessing that word generally equates with insanity, which is evident here in abundance.
Fortunately it's extremely heavily weighted and not universal (or even common).
Why would anyone want to chase people away from AUPH? Seems so bizarre, even bordering on evil.
Nothing good seems to come easy. Better days are coming.
$20 seems actually about right- what about later?
$40 seems in the ballpark...but my "Crystal Ball" historically has proven to have about the same efficacy as a "Magic 8-Ball".
Perfect! Dilly Dilly
I appreciate your persistence to get even a solitary name. None is the answer as expected.
Nice try- I gather this is the response:
You have pinpointed your difficulty. Time to get to work researching it, but first please respond to Jess's request.
"Biotech M&A takes off as Sanofi and Celgene spend $20 billion"
I expect a lot more of this- can't hurt AUPH as well. BP has $250 Billion to repatriate from overseas.
https://www.reuters.com/article/us-biotech-m-a/biotech-ma-takes-off-as-sanofi-and-celgene-spend-20-billion-idUSKBN1FB20V?il=0
"...LN patients will have many choices to select from..."
Nope- LN and SLE are different. Research it and see.
"It is there Jess, don't be lazy! "
I think it's next to the Unicorn.
"New Year Rings In New Hope for People Affected by Lupus"
https://www.lupus.org/general-news/entry/new-year-rings-in-new-hope-for-people-affected-by-lupus
As in, "holding a lowly pair of deuces against a straight flush, after a failed bluff he folded and then snuck out the back door"?
Interesting defense of distortion. Facts are pesky things.
"If you get all the facts, your judgment can be right; if you don't get all the facts, it can't be right."
Bernard Baruch